# BD to Announce Financial Results for its Third Quarter of Fiscal 2026
Canonical URL: https://biopharmsignal.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2026-fae7aaa2
Ticker: BDX
Company: Becton Dickinson
Source: Becton Dickinson
Published: 2026-07-09 20:15 EST
Original Source URL: https://investors.bd.com/news-events/press-releases/detail/963/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2026
## Summary

FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology…...

## Article Body
, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026 to discuss the Company's financial results for its third quarter of fiscal year 2026, which ended on June 30, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors , and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will include summary financial information for the quarter. The news release and related presentation materials will be made available at www.bd.com/investors .

About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ , X @BDandCo or Instagram @becton_dickinson .

View original content: https://www.prnewswire.com/news-releases/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2026-302822219.html

SOURCE BD (Becton, Dickinson and Company)

Released July 9, 2026
## Recent Company News
- 2026-07-09 20:15 EST — [BD to Announce Financial Results for its Third Quarter of Fiscal 2026](https://biopharmsignal.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2026-fae7aaa2) — Source: Becton Dickinson
- 2026-06-25 13:46 EST — [BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System](https://biopharmsignal.com/news/BDX/bd-awarded-vizient-innovative-technology-contract-for-centrovena-onetm-insertion-system) — Source: Becton Dickinson
- 2026-06-25 13:46 EST — [BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System](https://biopharmsignal.com/news/BDX/bd-delivers-kidney-stone-care-for-urology-teams-with-the-elyratm-thulium-fiber-laser-system) — Source: Becton Dickinson
- 2026-06-25 13:46 EST — [Peter Menziuso Named EVP and President, BD Interventional](https://biopharmsignal.com/news/BDX/peter-menziuso-named-evp-and-president-bd-interventional) — Source: Becton Dickinson
- 2026-06-25 13:46 EST — [BD Reports Second Quarter Fiscal 2026 Financial Results](https://biopharmsignal.com/news/BDX/bd-reports-second-quarter-fiscal-2026-financial-results) — Source: Becton Dickinson
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)